Product Name: Format/Size Descriptions Download
Dinucleoside Mimetics for RNA 696 compounds
For cherry-picking
Update: 2022-04
Systematic analysis of published small molecules with declared RNA activity has revealed several prominent structural elements that can be used as design templates for the creation of novel chemical libraries for RNA drug discovery. In particular, a combination of aromatic heterocyclic rings such as nucleobases or bioisosteric analogs with a saturated linear or ring component connected via a carbon-carbon bond are very common motifs among RNA-bound ligands with favorable drug-like properties. This observation confirms earlier published data suggesting that molecules having a favorable carbon bond saturation (defined by Fsp3) represent “biologically relevant chemical space” . In the case of RNA ligands, the right balance of aromaticity and saturation embedded in the RNA-compatible molecular framework may enhance binding probability. ASINEX have identified several such advantageous combinations.
Macrocycles for RNA 1790 compounds
For cherry-picking
Update: 2020-10
Fragments for RNA 1065 compounds
For cherry-picking
Update: 2020-10
RNA-targeting Small Molecules

(RNA targeted library)
(RNA compound library)
1862 compounds
For cherry-picking
Update: 2019-04
Modulation of the functional roles of RNAs in prokaryotic and eukaryotic cells with small molecules is becoming increasingly important in drug discovery. Unfortunately, to this point, there has been little clinical success involving RNA-binding small molecules. We, therefore, believe that a critical component for future RNA-directed drug discovery is access to the appropriate screening collection containing small molecules with an increased probability of engaging the target in an advantageous way. The choice of such a library could be based on structural knowledge of the binding cavity, the physicochemical properties complementary to RNA, along with other pharmacological properties such as cellular permeability.

In order to understand the scope of potentially druggable RNA targets and applicable screening libraries we analyzed RNA structures in the PDB database extracting 30 of the most promising macromolecule-ligand complexes. Based on these 30 RNA structures, we have created 16 pharmacophore queries that capture the characteristic features of a small molecule ligand bound to RNA. We then applied the resulting queries in searching through ASINEX BioDesign and Elite collections. These searches resulted in several hundred molecules that could be tagged with a particular pharmacophore.
Preferred RNA-binding motifs
2-phenyl benzimidazole
80 compounds
Pre-Plated Set
Release: 2017
A small molecule Targapremir-210 belonging to the 2-phenyl benzimidazole scaffold was shown to bind to the Dicer site of the miR-210 hairpin precursor inhibiting production of the mature miRNA. miR-210 regulates hypoxia inducible factors and plays a critical role in cancer maintenance. Small molecules that can selectively target specific miRNAs are promising therapeutic agents against several cancers.
Inhibitors of miсroRNA-21
80 compounds
Pre-Plated Set
Release: 2017
Small molecules that can bind directly to miR-21 have been suggested as a promising new therapy for the treatment of cancer. Screening a large library of druglike small molecules has identified several chemotypes that bind to the pre-miR-21 hairpin with high selectivity against other oligonucleotides. The most potent hit molecules share the common 1-amino-3-(9H-carbazol-9-yl)propan-2-ol scaffold which can be considered a privileged fragment.
Inhibitors of miсroRNA-29
80 compounds
Pre-Plated Set
Release: 2017
It has been hypothesized that compounds having at least one basic nitrogen are favored due to possible electrostatic interaction with negatively charged RNAs. In a paper submitted by the Prof. Nakatani group, several small molecules were disclosed exhibiting detectable affinity to pre-miR-29a - a miRNA involved in multiple pathophysiological processes. Analogs of one of the hit molecules (S-6) have been included in this library.

Ludmila Sadovenko

North America

Mark Parisi


Toll Free: +1 877 ASINEX1

Tel: +1 336 721 1617

Fax: +1 336 721 1618

N.Chestnut St., Ste.104

Winston-Salem, NC 27101



Galina Afanasyeva


Tel: +31 (0) 203416183

Klaprozenweg 75C, 1033NN

Amsterdam, The Netherlands


Shingo Ota


Tel: 080-3401-9097

30-2 Higashihazu, Nishio,

Aichi Japan

Your cart is empty
Thanks for your order
We will contact you shortly